Company* (Country; Symbol) | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
Agilent Technologies Inc. (NYSE:A) | Signature Genomic Laboratories LLC* | Long-term agreement in which Agilent will supply custom oligonucleotide microarrays based on the Signature-designed Signature Chip Oligo Solution for the detection of chromosome abnormalities in individuals with mental retardation/development delay, autism and congenital anomalies | Further terms were not disclosed (5/15) |
CuraGen Corp. (CRGN) | TopoTarget A/S (Denmark; CSE: TOPO) | Agreement for CuraGen to sell its cancer drug belinostat | TopoTarget will takeover the product for $26M in cash and $5M in shares, as well as $6M in milestone payments related to future net sales and sublicenses; Topo-Target plans to move the product into a Phase III trial for patients with peripheral T-cell lymphoma (4/22) |
Sequenom Inc. (SQNM) | Invitrogen Corp. (IVGN) | Agreement under which Invitrogen will be the exclusive distributor for Sequenom's MassARRAY systems and consumable products in Central and South America | Financial terms were not disclosed (5/1) |
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange. | |||